Equities Analysts Set Expectations for XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities researchers at William Blair lifted their FY2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a research report issued on Tuesday, November 4th. William Blair analyst M. Minter now expects that the biopharmaceutical company will post earnings per share of ($4.26) for the year, up from their previous estimate of ($4.32). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. William Blair also issued estimates for Xenon Pharmaceuticals’ Q4 2025 earnings at ($1.21) EPS, Q1 2026 earnings at ($0.95) EPS, Q2 2026 earnings at ($1.15) EPS, Q3 2026 earnings at ($1.19) EPS, Q4 2026 earnings at ($1.25) EPS, FY2026 earnings at ($4.53) EPS and FY2027 earnings at ($5.48) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.01. During the same period last year, the business posted ($0.81) EPS. The company’s revenue was up .0% compared to the same quarter last year.

A number of other brokerages have also issued reports on XENE. Needham & Company LLC reiterated a “buy” rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday. Royal Bank Of Canada boosted their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday. Wedbush boosted their price target on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 12th. Finally, Bloom Burton raised Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $53.70.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $38.66 on Thursday. Xenon Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $46.00. The firm has a market capitalization of $2.98 billion, a P/E ratio of -10.89 and a beta of 1.10. The business has a 50 day simple moving average of $39.40 and a 200 day simple moving average of $35.43.

Insider Activity

In other news, CEO Ian Mortimer sold 25,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $40.16, for a total transaction of $1,004,000.00. Following the sale, the chief executive officer directly owned 31,302 shares of the company’s stock, valued at $1,257,088.32. The trade was a 44.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.07% of the stock is owned by company insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Holocene Advisors LP acquired a new position in Xenon Pharmaceuticals during the second quarter valued at $56,637,000. Geode Capital Management LLC raised its position in Xenon Pharmaceuticals by 1,294.2% during the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock valued at $30,369,000 after buying an additional 900,746 shares during the period. Braidwell LP raised its position in Xenon Pharmaceuticals by 33.0% during the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock valued at $112,837,000 after buying an additional 895,154 shares during the period. Vestal Point Capital LP raised its position in Xenon Pharmaceuticals by 53.8% during the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $62,600,000 after buying an additional 700,000 shares during the period. Finally, Commodore Capital LP raised its position in Xenon Pharmaceuticals by 30.1% during the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after buying an additional 700,000 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.